Paul HOCKINGS (Antaros Medical)  SITE

Antaros Medical is pioneering imaging methodologies, using magnetic resonance imaging (MRI) and positron emission tomography (PET), designing and delivering clinical studies for decision making in drug development. Our unique offering is based on three key elements – an extensive drug development experience, deep disease area/biology knowledge and cutting-edge imaging methodologies. The disease area focus is cardiometabolic diseases (including NAFLD / NASH and chronic kidney disease) and oncology. The company has a global network of partners and customers, including both large and small drug development companies, and is a partner in several European research consortia, such as the Innovative Medicine Initiative (IMI) and COST. The company is based in the BioVentureHub in Mölndal and in Uppsala, where Antaros Corelab is based as well.

Antaros Medical is part of the IMI TRISTAN consortium working to validate imaging biomarkers for use in drug safety assessment. TRISTAN is validating gadoxetate DCE MRI for use in drug safety.

  • Diabetes Obes Metab. 2020;22:1094-1101. Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.Johansson L, Hockings PD, Johnsson E, Dronamraju N, Maaske J, Garcia-Sanchez R, Wilding JPH. PubMed
  • MAGMA. 2020 Feb;33:1-2. Special issue on magnetic resonance imaging biomarkers of renal disease. Hockings P, Laustsen C, Joles JA, Mark PB, Sourbron S. PubMed
  • MAGMA. 2020;33:163-176. Consensus-based technical recommendations for clinical translation of renal T1 and T2 mapping MRI. Dekkers IA, de Boer A, Sharma K, Cox EF, Lamb HJ, Buckley DL, Bane O, Morris DM, Prasad PV, Semple SIK, Gillis KA, Hockings P, Buchanan C, Wolf M, Laustsen C, Leiner T, Haddock B, Hoogduin JM, Pullens P, Sourbron S, Francis S. PubMed
  • Magn Reson Imaging. 2019;59:121-129. Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systems. Waterton JC, Hines CDG, Hockings PD, Laitinen I, Ziemian S, Campbell S, Gottschalk M, Green C, Haase M, Hassemer K, Juretschke HP, Koehler S, Lloyd W, Luo Y, Mahmutovic Persson I, O'Connor JPB, Olsson LE, Pindoria K, Schneider JE, Sourbron S, Steinmann D, Strobel K, Tadimalla S, Teh I, Veltien A, Zhang X, Schütz G. PubMed
  • Nephrol Dial Transplant. 2018;33(suppl_2):ii4-ii14. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, Garcia-Fernandez N, Golay X, Gordon I, Grenier N, Hockings PD, Jensen JD, Joles JA, Kalra PA, Krämer BK, Mark PB, Mendichovszky IA, Nikolic O, Odudu A, Ong ACM, Ortiz A, Pruijm M, Remuzzi G, Rørvik J, de Seigneux S, Simms RJ, Slatinska J, Summers P, Taal MW, Thoeny HC, Vallée JP, Wolf M, Caroli A, Sourbron S. PubMed
  • PLoS One. 2018;13:e0197213. A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function. Karageorgis A, Lenhard SC, Yerby B, Forsgren MF, Liachenko S, Johansson E, Pilling MA, Peterson RA, Yang X, Williams DP, Ungersma SE, Morgan RE, Brouwer KLR, Jucker BM, Hockings PD. PubMed
  • Non-invasive pre-clinical and clinical imaging of liver transporter function relevant to drug induced liver injury in Drug-induced liver toxicity. Methods in pharmacology and toxicology. Editors: Chen M, Will Y. Humana Press, New York, NY. 2018;627-651.  Kenna JG, Waterton JC, Baudy A, Galetin A, Hines CD, Hockings PD, Patel M, Scotcher D, Sourbron S, Ziemian S, Schuetz G. Link
  • How imaging biomarkers are transforming drug development in Drug Target Review. 2017;1,48-51. Waterton JC, Hockings PD, Maynard J, Roberts C. Link
  • Clinical MRI studies of drug efficacy and safety. eMagRes in Handbook of pharmaceutical NMR. 2015;4,345-453. Reid DG, Hockings PD, Saeed N.  eds. Everett JR, Lindon JC, Wilson ID, Harris RK. 2015. Link
  • Toxicol Sci. 2014;140:3-15. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Cove-Smith L, Woodhouse N, Hargreaves A, Kirk J, Smith S, Price SA, Galvin M, Betts CJ, Brocklehurst S, Backen A, Radford J, Linton K, Roberts RA, Schmitt M, Dive C, Tugwood JD, Hockings PD, Mellor HR. PubMed
  • NMR Biomed. 2013;26:1258-70. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD. PubMed
  • Magnetic Resonance Imaging in pharmaceutical safety assessment in Drug discovery and evaluation: safety and pharmacokinetic assays (Second Edition). Editors: Vogel HG, Hock HJ, Maas J, Mayer D, Springer Verlag, Berlin Heidelberg. 2013;561-571. Hockings PD. Link
  • In vivo MRI/S for the safety evaluation of pharmaceuticals in New applications of NMR in drug discovery and development. Editors: Garrido L, Beckmann N. The Royal Society of Chemistry, Cambridge. 2013; 361-375. Hockings PD, Powell H. Link

PubMed

Mölndal, Sweden

Last update: August 2021